Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Fierce 15 nominations are now open! We're looking for the best and brightest in biotech.
bispecific antibodies
Biotech
Novo Nordisk's Hemlibra rival hits goals in phase 3
A phase 3 trial of a challenger to the blockbuster hemophilia drug hit its primary endpoint, clearing the path for a filing for approval this year.
Nick Paul Taylor
May 14, 2024 9:16am
FDA blocks approval of Regeneron's blood cancer drug
Mar 25, 2024 9:25pm
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Mar 15, 2024 8:35am
Pfizer cuts 3 assets as R&D spend drops 24% in Q4
Jan 30, 2024 11:37am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
Regeneron's 'best-in-class' myeloma drug spurs 100% side effects
Dec 7, 2023 7:00am